Therapeutic Antibodies

Monoclonal antibodies
#Antibodies #Bioproduction #Monoclonal antibodies #Tokyo University of Science

Researchers from Japan take a new approach to enhancing antibodies

Researchers from Tokyo University of Science (TUS) have found a simple, low-cost way to optimise the production of monoclonal antibodies (mAbs) and reduce manufacturing costs. Dr Kyohei Higashi, Associate Professor at TUS, along with a team of researchers, conducted a study to explore the effects of… Read More

#News

#Therapeutic Antibodies

Guide: Therapeutic Antibodies Guide Twist

DDW has published the latest edition in its guide series ‘The global innovation and opportunity in therapeutic antibody development’.   The DDW Therapeutic Antibodies Guide looks at the trajectory of antibody therapies in 2024 and use-cases across disease areas.  Download to learn about:   Therapeutic antibody potential in 2024  Therapeutic antibodies… Read More

#DDW Guides

#Arxx Therapeutic #Calluna Pharma #Funding #Immune system #Monoclonal antibodies #Oxitope Pharm #Therapeutic Antibodies

Calluna Pharma announces €75 million Series A financing 

Oxitope Pharma and Arxx Therapeutics, companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, has announced their merger to form Calluna Pharma.   Calluna has raised €75 million in a series A financing and is backed by Oxitope and Arxx’s existing… Read More

#Business & Investment #News

Human antibodies
#Animal models #Antibodies #HIV #Immunology / Virology & Vaccines #NIAID

Antibodies protect against HIV in animal studies

Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV vaccine for people. The antibodies – a human broadly neutralsing antibody and two antibodies isolated from previously vaccinated monkeys – target… Read More

#News

amino acids chain
#Biologics #Drug discovery #Infographic #Nanomedicine / nanotechnology #Proteins

Compare methods for thermal stability assessment of proteins

A new infographic ‘Four methods for thermal stability assessment of therapeutic proteins‘ is now available to download for free. Thermal stability is among the most common critical quality attributes (CQAs) used for early developability assessment of biologics. In this infographic, learn about four methods for thermal stability… Read More

#News

#Biologics #Drug discovery #Infographic #Nanomedicine / nanotechnology #Proteins

Four methods for thermal stability assessment of proteins

Thermal stability is among the most common critical quality attributes (CQAs) used for early developability assessment of biologics. In this infographic, learn about four methods for thermal stability assessment of proteins – what they measure, what the data tells you, and their benefits and limitations. While each provides unique value,… Read More

#Intelligence #Resources

Antibodies attack Covid-19
#Antibodies #Covid variants #Covid-19 #Covid-19 treatment #ExeVir Bio #Omicron

Antibody cocktail effective against emerging Covid-19 variants

Biotech company ExeVir Bio has revealed new data demonstrating that its antibodies are effective in neutralising currently circulating Covid-19 Omicron variants. The company says that all authorised SARS-CoV-2 therapeutic antibodies that have been used in the clinic show severe to complete loss of virus neutralisation potency… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

New DDW Highlights podcast: 15 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week has seen a number of significant discoveries by researchers in academic institutions,… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

This week in drug discovery (8-12 January) 

News round-up for 8-12 January by DDW Digital Content Editor Diana Spencer. This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery. Perhaps most importantly,… Read More

#News

GSK offices
#Asthma #GSK #Mergers and acquisitions #Monoclonal antibodies #Respiratory

GSK expands respiratory pipeline with Aiolos Bio acquisition

GSK is to acquire Aiolos Bio for a $1 billion upfront payment and up to $400 million in regulatory milestone payments. The acquisition includes Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for asthma, with potential for additional indications. Read More

#Business & Investment #News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

New DDW Highlights podcast for 8 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The start of 2024 has seen quite a bit of regulatory activity, with the… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

This week in drug discovery (1-5 January) 

News round-up for 1-5 January by DDW Digital Content Editor Diana Spencer. The start of 2024 has seen quite a bit of regulatory activity, with the UK MHRA’s launch of a new procedure for assessing drugs, along with significant regulatory approvals for therapeutics for cytomegalovirus, melanoma,… Read More

#News

#AbCheck #Ampersand Biomedicines #Antibodies #Mergers and acquisitions

Ampersand Biomedicines acquires antibody discovery company

Ampersand Biomedicines has announced the acquisition of antibody discovery technology company AbCheck, previously a wholly-owned subsidiary of Affimed. Ampersand Biomedicines launched out of Flagship Pioneering in March 2023. The company hopes the addition of AbCheck’s discovery platform will enable cost-effective and strategic acceleration of its own Address, Navigate, Determine (AND)… Read More

#Business & Investment #News

Monoclonal antibody
#Bristol Myers Squibb #Melanoma #MHRA #Monoclonal antibodies #Project Orbis

Nivolumab-relatlimab combination for melanoma approved in UK

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bristol Myers Squibb’s advanced melanoma drug Opdualag (nivolumab-relatlimab) for patients from the age of 12. Opdualag was authorised through Project Orbis, a global partnership between the MHRA, the Therapeutics Goods Administration in Australia, Health Canada, the Health Sciences Authority… Read More

#News #Regulatory

Human cell
#Biologics #Cell and gene therapy #Cytomos #Lab technology #Single-cell analysis

Can cell analysis tech help streamline biotech product development?

Scotland-based biotech Cytomos has launched its newly patented AuraCyt cell analysis technology brand. According to the company, AuraCyt provides information on cell properties and can be incorporated in-line, allowing real-time monitoring of cell manufacturing events and predicting manufacturing success. It is designed to collect data that measures the intrinsic properties… Read More

#Business & Investment #News